IL33 and asthma: Numerous studies have shown that local administration or lung specific transgenic expression of IL-33 is sufficient to provoke various asthma-associated symptoms, including inflammatory cellular infiltration, airway hyperresponsiveness and remodeling, collagen disposition, airway smooth muscle hypertrophy, goblet cell hyperplasia, increased pulmonary vascularity and tissue damping [12,13,14].